Literature DB >> 2526330

Biodistribution and scintigraphy of 11C-toremifene in rats bearing DMBA-induced mammary carcinoma.

L Kangas1, M Haaparanta, R Paul, D Roeda, H Sipilä.   

Abstract

A new antioestrogenic antitumour compound toremifene was labeled with 11C or 3H. The tissue distribution and tumour uptake of the compounds in DMBA induced breast tumour bearing rats was investigated. 11C-toremifene was localized by gamma camera scintigraphy and tissue counting. 3H-Toremifene was determined by liquid scintillation counting after oxidizing the tissue samples. Toremifene was distributed to several tissues due to the lipophilicity and was not taken up specifically by the tumours to any great extent. However, the radioactivity of the tumours increased as a function of time although it declined e.g. in the liver. The accumulation to the tumour was a slow process and cannot be followed up reliably by such short half-life radionuclides as 11C. The tumour uptake properties of toremifene resemble those of tamoxifen and several other oestrogen receptor binding compounds. These substances have limited use in diagnosing and imaging oestrogen receptor rich breast tumours in man.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2526330     DOI: 10.1111/j.1600-0773.1989.tb00668.x

Source DB:  PubMed          Journal:  Pharmacol Toxicol        ISSN: 0901-9928


  5 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of toremifene.

Authors:  T L Taras; G T Wurz; G R Linares; M W DeGregorio
Journal:  Clin Pharmacokinet       Date:  2000-11       Impact factor: 6.447

Review 3.  Toremifene. A review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer.

Authors:  L R Wiseman; K L Goa
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 4.  Pharmacokinetics of selective estrogen receptor modulators.

Authors:  Karla C Morello; Gregory T Wurz; Michael W DeGregorio
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients.

Authors:  E A Lien; K Wester; P E Lønning; E Solheim; P M Ueland
Journal:  Br J Cancer       Date:  1991-04       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.